Systemic Interventions For Treatment Of Stevens‐Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), And SJS/TEN Overlap Syndrome
A. Langley, B. Worley, J. Pardo, J. Beecker, T. Ramsay, Arturo Saavedra, Jean Farrell-McCawley, P. Tugwell
Published 2018 · Medicine
Download PDFAnalyze on Scholarcy
This paper references
Toxic epidermal necrolysis: current evidence, practical management and future directions
T. Chave (2005)
Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.
S. Bastuji-Garin (1993)
Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid.
G. Singh (2013)
Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases.
C. Prins (2003)
Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
J. Roujeau (1995)
Toxic epidermal necrolysis in a child successfully treated with infliximab.
V. Scott-Lang (2014)
Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis
L. Valeyrie-Allanore (2010)
Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis.
Agnieszka Wojtkiewicz (2008)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
J. Sterne (2016)
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
S. Hung (2005)
HLA‐B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese
Ying-Kit Cheung (2013)
Treatment of toxic epidermal necrolysis in North America.
R. Dodiuk-Gad (2015)
Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children.
P. Tristani-Firouzi (2002)
Cyclosporine for SJS/TEN: a case series and review of the literature.
Drew A. Reese (2011)
Treatment of toxic epidermal necrolysis with cyclosporin A.
J. Arévalo (2000)
Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches.
C. González‐Herrada (2017)
Medical genetics: A marker for Stevens–Johnson syndrome
Wen-hung Chung (2004)
Chapter 10: Addressing reporting biases
M. Egger (2011)
Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients-Exposed/Unexposed and Propensity Score-Matched Analyses.
F. Poizeau (2018)
Etanercept for Toxic Epidermal Necrolysis
G. Famularo (2007)
Lamotrigine‐induced toxic epidermal necrolysis treated with intravenous cyclosporin: A discussion of pathogenesis and immunosuppressive management
J. Sullivan (1996)
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis--A Comprehensive Review and Guide to Therapy. I. Systemic Disease.
Sahar Kohanim (2016)
Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience.
J. Trent (2003)
Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis
S. Zimmermann (2017)
Toxic epidermal necrolysis successfully treated with infliximab.
L. C. Zárate-Correa (2013)
Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients.
J. Revuz (1987)
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.
I. Viard (1998)
Interventions for toxic epidermal necrolysis.
S. Majumdar (2002)
SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.
S. Bastuji-Garin (2000)
Toxic Epidermal Necrolysis Treated with Intravenous High-Dose Immunoglobulins: Our Experience
M. Stella (2001)
Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome.
Y. Yamane (2016)
Saving the skin from drug-induced detachment
B. Nickoloff (2008)
Treatment of Epidermal Necrolysis with High-Dose Intravenous Immunoglobulins (IVIg)
O. Faye (2012)
Low N‐acetylating capacity in patients with Stevens‐Johnson syndrome and toxic epidermal necrolysis *
A. Dietrich (1995)
Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporin
I. Zaki (1995)
Etanercept therapy for toxic epidermal necrolysis.
A. Paradisi (2014)
Toxic epidermal necrolysis successfully treated with etanercept
E. Gubinelli (2009)
Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus successfully treated with a single dose of etanercept: report of three cases.
M. Napolitano (2013)
Stevens–Johnson syndrome and toxic epidermal necrolysis: a 20‐year single‐center experience
Jovan Lalosevic (2015)
A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population.
T. Patel (2013)
Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF.
E. Robak (2001)
Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor
P. Jarrett (1997)
Combination of Infliximab and High-Dose Intravenous Immunoglobulin for Toxic Epidermal Necrolysis: Successful Treatment of an Elderly Patient
Konstantinos Patmanidis (2012)
Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults.
D. Hsu (2016)
A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures.
B. Strom (1991)
Randomized, controlled trial of TNF-&agr; antagonist in CTL-mediated severe cutaneous adverse reactions
C. Wang (2018)
Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
P. Sekula (2013)
Regression Methods for Poisson Process Data
J. Lawless (1987)
Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine.
M. Kirchhof (2014)
Suprapharmacologic doses of intravenous dexamethasone followed by cyclosporine in the treatment of toxic epidermal necrolysis.
R. Rai (2008)
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.
M. McCormack (2011)
This paper is referenced by
Overlap SJS-TEN in a kid and management protocols
Sonali Mukherjee (2020)
Use of Etanercept in a Series of Pediatric Patients With Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Spectrum Disease.
Philip J Eliades (2020)